Results from the phase III KEYNOTE‐024 led to pembrolizumab approval as first‐line therapy for patients with previously untreated advanced NSCLC with a TPS ≥ 50% but without EGFR/ALK aberration as it significantly improved PFS and OS compared with standard platinum‐based chemotherapy [10, 87]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.